Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Double blind, placebo controlled, randomized clinical trial to evaluate the efficacy of ivermectin in preventing progression of disease in adult patients with early stages of COVID-19
Description: Time until deterioration of 2 or more points in an ordinal 7 points scale.
Measure: Time to event Time: 21 daysDescription: Clinical condition in an ordinal scale of 7 points, on day 2. Higher scores indicate worse outcomes
Measure: Clinical condition on day 2 Time: On day 2 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 5. Higher scores indicate worse outcomes
Measure: Clinical condition on day 5 Time: On day 5 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 8. Higher scores indicate worse outcomes
Measure: Clinical condition on day 8 Time: On day 8 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 11. Higher scores indicate worse outcomes
Measure: Clinical condition on day 11 Time: On day 11 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 15. Higher scores indicate worse outcomes
Measure: Clinical condition on day 15 Time: On day 15 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 21. Higher scores indicate worse outcomes
Measure: Clinical condition on day 21 Time: On day 21 (± 1 day) after randomizationDescription: Proportion of subjects who require hospitalization, use of supplementary oxygen for >24 hours or ICU admission
Measure: Proportion of subjects with additional care Time: 21 daysDescription: Proportion of subjects who die
Measure: Proportion of subjects who die Time: From randomization up to 28 daysDescription: Duration of supplementary oxygen, hospitalization, ICU stay
Measure: Duration of additional care Time: 21 daysDescription: Proportion of subjects who develop solicited adverse events
Measure: Adverse events Time: 21 daysDescription: Proportion of subjects who required discontinuation of the trial due to adverse events
Measure: Proportion of subjects who discontinue intervention Time: 21 days